Amphastar Pharmaceuticals (AMPH) Enterprise Value (2014 - 2026)

Amphastar Pharmaceuticals has reported Enterprise Value for 13 years, with the latest figure at $568.2 million in Q2 2026.

• On a quarterly basis, Enterprise Value fell 32.01% year-over-year to $568.2 million in Q2 2026; TTM through Jun 2026 was $568.2 million, a 32.01% decrease from a year earlier, with the FY2025 full-year figure at $939.6 million, down 39.24% from the prior year.
• Enterprise Value was $568.2 million for Q2 2026 at Amphastar Pharmaceuticals, down from $582.5 million in the prior quarter.
• The five-year high for Enterprise Value was $2.7 billion in Q4 2023, with the low at $568.2 million in Q2 2026.
• Average Enterprise Value over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value jumped 131.7% in 2023, then sank 54.27% in 2025.
• Over 5 years, Enterprise Value stood at $1.2 billion in 2022, then surged by 131.7% to $2.7 billion in 2023, then sank by 43.07% to $1.5 billion in 2024, then tumbled by 39.24% to $939.6 million in 2025, then slumped by 39.53% to $568.2 million in 2026.
• The last three Enterprise Value figures came in at $568.2 million (Q2 2026), $582.5 million (Q1 2026), and $939.6 million (Q4 2025), per Business Quant data.